Effect of beta blockers on sepsis outcome. 2009

Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
Department of Medicine, New York Medical College, Valhalla, NY, USA. drjosegc@hotmail.com

BACKGROUND The aim of this study was to investigate weather beta blockers are associated with an increased mortality in sepsis. METHODS Data on 83 patients with sepsis treated in ICU were analyzed from the retrospective chart review. The association between treatment with Beta blockers and mortality was analyzed by logistic regression in univariate model and after adjusting for the APACHE morbidity/ mortality scores. RESULTS Among 83 patients (mean age 56.2+/-17.3 years, female 51%, the mean APACHE score 74.8+/-23.3), 29 were treated with BB. Those treated with BB had APACHE score of 79.93+/-23.47 and those not treated with BB had APACHE score of 73.67+/-23.21. No significant difference between the traditional cardiovascular risk factors was found in both groups except for HTN. Treatment with BB was not significantly associated with mortality in the univariate (OR=1.83, 95% CI 0.59-5.69) nor multivariate model (OR=1.843, 95% CI 0.56-6.10). The APACHE score was a strong predictor of mortality (OR=1.04, 95% CI 1.01-1.06, p=0.02). This association was independent of BB use, and no significant interaction (p=0.72) between BB and APACHE score was observed. CONCLUSIONS We did not show a significant association between beta blockers and increased mortality in patients with sepsis. Sicker patients had an increase risk of death, and possibility that beta blocker use may have contributed to this risk cannot be completely ruled out. Our study was limited by a small sample size and retrospective design. Further investigations of potential benefits and side effect of beta blockers in patients with sepsis are warranted.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
January 2021, Clinical epidemiology,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
September 1979, British medical journal,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
October 1979, British medical journal,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
September 1979, British medical journal,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
December 2020, The American journal of emergency medicine,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
February 2009, Shock (Augusta, Ga.),
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
November 1980, British medical journal,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
August 1986, International journal of clinical pharmacology, therapy, and toxicology,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
January 1976, Eksperimentalna meditsina i morfologiia,
Jose Gutierrez, and Amin Hossam, and Roxana Lazarezcu, and El Kay, and Tatjana Rundek
July 2022, Journal of intensive care medicine,
Copied contents to your clipboard!